Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?

BACKGROUND: The use of continuing antipsychotic medication is an established evidence-based strategy for preventing relapse in people with schizophrenia, but medication adherence is known to be suboptimal. Covert non-adherence can be eliminated by the use of long-acting injectable (LAI) formulations...

Descripción completa

Detalles Bibliográficos
Autores principales: Paton, Carol, Okocha, Chike I., Patel, Maxine X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854225/
https://www.ncbi.nlm.nih.gov/pubmed/35186261
http://dx.doi.org/10.1177/20451253211072347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854225/
https://www.ncbi.nlm.nih.gov/pubmed/35186261
http://dx.doi.org/10.1177/20451253211072347

Ejemplares similares